Recent News
NEW HAVEN, Conn., July 29, 2020 (GLOBE NEWSWIRE) — Kleo Pharmaceuticals announced today that Doug Manion, MD, Chief Executive […] Read More...
Watch the Video to Learn More
Partnering Opportunities
Our technologies enable us to rapidly develop novel immunotherapies against targets of interest with potential partners.
Our Lead Programs
Kleo is rapidly advancing multiple candidates in oncology and infectious disease
Partnering Opportunities
Our technologies enable us to rapidly develop novel immunotherapies against targets of interest with potential partners.
Our Lead Programs
Kleo is rapidly advancing multiple candidates in oncology and infectious disease
Our Sciences
News
Kleo Pharmaceuticals, Unlocking the Versatility and Broad Applicability of Bispecific Small Molecules That Potentiate Endogenous IgG Kleo 072320–Private company spotlight
Read Morehttps://www.wtnh.com/news/health/coronavirus/new-haven-biotech-receives-5m-from-bill-melinda-gates-foundation-for-covid-19-treatment/
Read MoreThe Grant from the Bill & Melinda Gates Foundation Accelerates Company’s Efforts to Enter Clinical Trials by Early 2021 NEW […] Read More
Natural Killer (NK) Cells: Pushing the Next Wave of Immuno-Oncology Therapies https://lnkd.in/dFmQQj6 Password: 5J#j3@B+
Read MoreEvents
